Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
Although idiopathic pulmonary arterial hypertension is perceived as a progressive disease with a uniformly poor outcome, the natural history of disease is heterogeneous, with some patients dying within months of diagnosis and others living for decades. The course of the disease has also been altered by advances in medical therapies. The outcome of patients with other types of pulmonary arterial hypertension (PAH) has been less well characterized. Assessment of prognosis of such patients is important, as it influences both medical therapy and referral for transplantation. This chapter will provide evidence based recommendations to assess the prognosis of patients with PAH.
McLaughlin
Vallerie V
VV
University of Michigan, 1500 East Medical Center Dr, Women's Hospital-Room L3119, Ann Arbor, MI 48109-0273, USA. vmclaugh@umich.edu
Presberg
Kenneth W
KW
Doyle
Ramona L
RL
Abman
Steven H
SH
McCrory
Douglas C
DC
Fortin
Terry
T
Ahearn
Gregory
G
D015415:Biomarkers / Q000097:blood; D004452:Echocardiography; D004562:Electrocardiography; D019317:Evidence-Based Medicine; D005080:Exercise Test; D006801:Humans; D006976:Hypertension, Pulmonary / Q000503:physiopathology* / Q000628:therapy; D011379:Prognosis; D011651:Pulmonary Artery; D012129:Respiratory Function Tests; D012307:Risk Factors
D015415:Biomarkers